NOVAGO Therapeutics

NOVAGO Therapeutics AG specializes in developing advanced antibody therapeutics to enhance nerve growth and regeneration, focusing on spinal cord injuries and diabetic retinopathy. Founded in 2015 and headquartered in Schlieren, Switzerland, and The company was co-founded by Prof. Martin E. Schwab and Prof. Roger Nitsch. and the Dr. Stefan Moese is the present Chief Executive Officer of the company. NovaGo Therapeutics AG is dedicated to creating innovative therapies for nerve repair. NovaGo Therapeutics specializes in developing human antibody therapeutics aimed at enhancing nerve growth and regeneration, particularly in the context of spinal cord injuries and diabetic retinopathy. Their core product, NG004, is designed to block the Nogo-A receptor, which is known to inhibit nerve growth, thereby promoting nerve repair and functional recovery. This therapeutic approach has demonstrated efficacy in preclinical models, addressing the unmet medical need for patients suffering from spinal cord injuries, which can lead to significant loss of sensation and motor paralysis. The primary end-users of NovaGo’s products are patients affected by these debilitating conditions.Details regarding NovaGo Therapeutics' revenue structure are not publicly disclosed. However, the company operates through direct partnerships with clinical research institutions, enabling it to conduct trials and bring its products to market. The revenue generation model is based on collaborations with healthcare providers, research institutions, and possibly licensing agreements for its therapeutics. The firm’s flagship product, NG004, plays a critical role in its business strategy, as it represents a potential breakthrough in spinal cord injury treatment and serves as a focal point for attracting investments and partnerships aimed at advancing clinical trials.

1. Series B

   Aug 31, 2026

   Amount

   $30M

   Investors

   Locked

2. Series A

   Jan 4, 2019

   Amount

   $10M

   Investors

   Locked